

BIB

ProShares Ultra Nasdaq Biotechnology

Analyst Report

This ETF offers 2x daily long leverage to the broad-based NASDAQ Biotechnology Index, making it a powerful tool for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies. Investors should note that BIB's leverage resets on a daily basis, which results in compounding of returns when held for multiple periods. BIB can be a powerful tool for sophisticated investors, but should be avoided by those with a low risk tolerance or a buy-and-hold strategy.

ESG Themes and Scores

5.44/10

ESG Rate

21.19%

Global Percentile

15.92%

Peer Percentile

Performance Data

	BIB	ETF Database Category Average	Factset Segment Average
1 Month	3.35%	8.20%	3.35%
3 Month	-3.75%	18.59%	-3.75%
YTD Return	6.35%	21.37%	6.35%
1 Year Return	98.47%	80.12%	98.47%
3 Year Return	18.49%	22.61%	18.49%
5 Year Return	0.81%	3.48%	0.81%

Top 5 Holdings

Symbol	Holding	% Assets
Other	U.S. Dollar	29.46%
IQMM	ProShares GENIUS Money Market ETF	6.93%
GILD	Gilead Sciences, Inc.	4.72%
VRTX	Vertex Pharmaceuticals Incorporated	4.63%
AMGN	Amgen Inc.	4.56%

Vitals

Issuer	Proshare Advisors LLC
Brand	ProShares
Structure	ETF
Expense Ratio	0.95%
Inception	Apr 07, 2010
Index Tracked	NASDAQ Biotechnology Index (200%)

ETF Database Themes

Category	Leveraged Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Leveraged Equity: U.S. Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Exchange-specific
Weighting	Market Cap

